超重妇女产后身体组成:怀孕期间与饮食的关联
Ella Muhli1,2,3, Tero Vahlberg4, Lotta Saros1
1Integrative Physiology and Pharmacology Unit Institute of Biomedicine University of Turku Turku Finland.
Obesity science & practice
|October 16, 2025
概括
产后体重管理是代谢健康的关键. 怀孕期间的健康饮食改善了产后的身体脂肪趋势,而鱼油和益生菌没有影响.
科学领域:
- 生殖健康 生殖健康
- 营养科学 营养科学
- 代谢健康 代谢健康
背景情况:
- 产后体重管理对于预防未来的代谢障碍至关重要.
- 身体脂肪百分比,准确地通过空气位移胸膜学测量,是肥胖的一个关键指标.
- 了解产后身体组成的变化对于母亲的健康至关重要.
研究的目的:
- 为了确定体重过重的妇女在产后两年内身体脂肪百分比的轨迹.
- 研究鱼油,益生菌,饮食,妊娠期糖尿病和妊娠期体重增加对产后身体组成的影响.
主要方法:
- 一项随机对照试验的二次分析,涉及439名超重或肥胖妇女.
- 干预包括从怀孕早期到产后六个月的鱼油和/或益生菌.
- 在多个分娩后的时间点使用空气位移囊法测量身体成分;在怀孕早期评估饮食.
主要成果:
- 观察到三个不同的分娩后体脂百分比轨迹,但脂肪率没有持续下降.
- 在怀孕初期,健康的饮食模式和高的饮食质量指数 (IDQ) 得分与在产后第一年内体脂的下降趋势有关.
- 鱼油和/或益生菌干预措施没有显著影响产后身体组成.
结论:
- 怀孕期间整体良好的饮食质量可能会对超重或肥胖妇女产后的身体组成产生积极的影响.
- 怀孕早期的饮食模式和质量是产后身体脂肪管理的重要因素.
- 在这项研究中,补充干预措施 (鱼油,益生菌) 没有证明对分娩后的身体组成有影响.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Drug Dosing: Obese Patients
218
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
218
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
245
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
245
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165


